IRIS
ZAMPINO, Rosa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 13.414
NA - Nord America 5.983
AS - Asia 4.869
SA - Sud America 890
AF - Africa 68
Continente sconosciuto - Info sul continente non disponibili 13
OC - Oceania 2
Totale 25.239
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 8.742
US - Stati Uniti d'America 5.894
SG - Singapore 1.878
IE - Irlanda 1.561
CN - Cina 1.042
HK - Hong Kong 967
UA - Ucraina 793
BR - Brasile 752
GB - Regno Unito 639
IT - Italia 440
DE - Germania 433
SE - Svezia 251
VN - Vietnam 234
FI - Finlandia 218
TR - Turchia 189
KR - Corea 186
GR - Grecia 154
JP - Giappone 128
IN - India 89
FR - Francia 75
AR - Argentina 59
CA - Canada 33
AT - Austria 32
MX - Messico 32
BD - Bangladesh 31
EC - Ecuador 24
IQ - Iraq 22
BE - Belgio 20
ID - Indonesia 16
MA - Marocco 16
UZ - Uzbekistan 14
ZA - Sudafrica 14
NL - Olanda 13
CO - Colombia 12
EU - Europa 12
VE - Venezuela 12
CL - Cile 10
EG - Egitto 8
KE - Kenya 8
PK - Pakistan 8
IR - Iran 7
PE - Perù 7
ES - Italia 6
IL - Israele 6
LT - Lituania 6
PL - Polonia 6
PY - Paraguay 6
SA - Arabia Saudita 6
TN - Tunisia 6
AL - Albania 5
KZ - Kazakistan 5
PA - Panama 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
HN - Honduras 4
MY - Malesia 4
NP - Nepal 4
SN - Senegal 4
UY - Uruguay 4
AZ - Azerbaigian 3
BH - Bahrain 3
DZ - Algeria 3
HU - Ungheria 3
KG - Kirghizistan 3
KW - Kuwait 3
LB - Libano 3
BG - Bulgaria 2
CR - Costa Rica 2
JM - Giamaica 2
PH - Filippine 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AM - Armenia 1
AO - Angola 1
AU - Australia 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EE - Estonia 1
GE - Georgia 1
GT - Guatemala 1
HR - Croazia 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
Totale 25.228
Salva come PNG Salva come JPEG
Città #
Moscow 2.952
Dublin 1.560
Jacksonville 1.201
Santa Clara 977
Hong Kong 967
Singapore 712
Chandler 707
Princeton 243
Roxbury 195
Seoul 186
New York 173
Ann Arbor 143
Cambridge 142
Ashburn 137
Beijing 128
Woodbridge 121
Boardman 115
Dallas 109
Bremen 108
Wilmington 108
Hefei 105
Medford 105
The Dalles 89
Ho Chi Minh City 82
Bengaluru 61
Jinan 56
San Mateo 55
São Paulo 54
Munich 52
Des Moines 51
Mountain View 50
Nanjing 48
Düsseldorf 45
Hanoi 42
Shenyang 42
Nuremberg 41
Naples 36
Norwalk 28
Napoli 27
Caserta 25
Belo Horizonte 21
Los Angeles 21
Brussels 20
Washington 20
Changsha 19
Zhengzhou 19
Brasília 18
Guangzhou 18
Helsinki 18
Rio de Janeiro 18
Houston 17
Lanzhou 17
Tianjin 17
Ningbo 16
Bologna 15
Campinas 15
Marano Di Napoli 14
Haikou 13
Hangzhou 13
Taizhou 13
Baghdad 12
Salvador 12
Tashkent 12
Toronto 12
Vienna 12
Guadalupe 11
Haiphong 11
Hebei 11
Nanchang 11
Porto Alegre 11
Seattle 11
Auburn Hills 10
Istanbul 10
San Francisco 10
Biên Hòa 9
Casablanca 9
Council Bluffs 9
Da Nang 9
Guayaquil 9
Rome 9
Taiyuan 9
Tokyo 9
Turku 9
Bari 8
Brooklyn 8
Dhaka 8
Goiânia 8
Mauá 8
Milan 8
Ottawa 8
Venice 8
Volvera 8
Athens 7
Curitiba 7
Fortaleza 7
Guarulhos 7
Kunming 7
Manaus 7
Quito 7
Thái Nguyên 7
Totale 12.785
Salva come PNG Salva come JPEG
Nome #
Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C 188
Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C. 177
Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: Effects of hepatitis B virus co-infection and interferon treatment 175
Cannabinoid receptor 2-63 QQ variant is associated with persistently normal aminotransferase serum levels in chronic hepatitis C 170
Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms 162
Cannabinoid Receptor 2 (CB2) Q63 variant in chronic hepatitis C: an association with a more severe hepatocellular necrosis. 160
Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration 157
Chronic HCV infection and neurological and psychiatric disorders: an overview. 152
Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review 149
CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. 148
Cannabinoid receptor 2 (CB2) Q63 variant is associated with a severe histological activity index in patients with chronic hepatitis C 147
Analisi della regione del core promoter del virus dell’epatite B (HBV) in pazienti guariti da una malattia oncoematologica con infezione cronica da HBV o da HBV-HCV tre anni dopo sieroconversione ad anti-HBe. 147
Chronic HCV Infection is risk of atherosclerosis. Role of HCV and HCV-related steatosis 145
Analisi della regione del core promoter del virus dell’epatite B (HBV) in pazienti guariti da una malattia oncoematologica con infezione cronica da HBV o da HBV-HCV tre anni dopo sieroconversione ad anti-HBe 140
Chronic hepatitis B infection in pediatric patients cured of oncologic diseases: natural history and effect of interferon treatment 140
Ruolo eziologico e patogenetico del virus dell'epatite C (HCV) nella crioglobulinemia mista (CM) in pazienti con epatite cronica (EC). 139
. Cinetica precoce dell’HCV-RNA in pazienti con epatite cronica: correlati clinico-virologici e valore predittivo la risposta al trattamento antivirale 135
Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study 134
Atherosclerosis and chronic hepatitis C virus (HCV) infection: Role of liver steatosis 132
Clinical efficacy and safety of cefiderocol for resistant gram-negative infections: a real-life, single center experience 130
Nocardiosi polmonare in pazienti con trapianto di cuore: casi clinici 130
Aspetti clinico terapeutici della crioglobulinemia mista associata all’epatite cronica C: esperienza su un ampia casistica. 130
Clinical results with the use of ceftaroline and ceftobiprole: real-life experience in a tertiary care hospital 129
A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon 128
Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. 127
Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes 127
Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals 126
The impact of the CB2-63 polymorphism on the histological presentation of chronic hepatitis B. 126
PNPLA3 l148M variant as a risk factor for carotid atherosclerosis in chronic epatiti C 126
ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens. 126
ABCB4 and ABCB11 mutations in intrahepatic cholestasis of pregnancy in an Italian population 125
Comparison of dual HBV-HCV versus single HBV or HCV infections in a previous oncologic pediatric population. 125
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19 125
L'endocardite da Enterococco: nostra esperienza nel periodo 1988-93. 123
Can we go for a shorter treatment course in chronic hepatitis C? More inspiring cases 123
Virological patterns of HCV patients with failure to interferon-free regimens. 123
Clinical significance and prognostic value of hemostasis parameters in 337 patients with acute infective endocarditis 123
La epatite cronica da HCV con steatosi si associa ad elevato rischio aterosclerotico. 122
No effect of MTP polymorphisms on PNPLA3 in HCV-correlated steatosis 122
HCV-related steatosis and risk of atherosclerosis 121
Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection 120
Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B 120
Esperienza con l'interferone linfoblastoide nelle epatiti croniche virali 120
Prognostic Value of Decreased High-Density Lipoprotein Cholesterol Levels in Infective Endocarditis 120
Treatment of chronic hepatitis B in children with prednisone followed by alpha-interferon: a controlled randomized study 118
Immunocompromised patients with HBsAg a determinant mutants: comparison of HBsAg diagnostic assays 118
Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients 118
Favourable effect of alpha-interferon treatment in HBeAb/HBV-DNA positive chronic hepatitis B. 118
Aspetti diagnostici di mutanti della regione HBsAg in pazienti immunocompromessi con riattivazione dell’infezione da virus dell’epatite B (HBV). 117
Hepatic steatosis and necro-inflammatory activity overestimated liver stiffness by transient elastography in staging liver fibrosis in chronic hepatitis C 117
Associating enterococcal endocarditis and colorectal neoplasia: is colonoscopy mandatory? – Authors’ reply 117
Risk factors and outcome of multidrug-resistant infections after heart transplant: A contemporary single center experience 117
Leukocyte interferon-alpha and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon 116
Ruolo patogenetico dell'adiponectina nella steatosi associata ad epatite C 116
Infezioni polmonari micotiche e da nocardia nel paziente cardiotrapiantato: caratteristiche cliniche e trattamento 115
EFFICACIA DEL TRATTAMENTO CON INTERFERONE RICOMBINANTE E LINFOBLASTOIDE IN PAZIENTI CON EPATITE CRONICA DA HCV 115
HCV RNA levels in serum, liver and PBMC of chronic hepatitis C patients: pathological and therapeutic significance. 115
Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B 115
Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. 114
Celiachia silente in pazienti con epatite C: prevalenza, effetto del trattamento con alfa-interferone sull’attivazione della malattia ed evoluzione clinica 114
Viral Hepatitis C 114
Predictors of long-term mortality in left-sided infective endocarditis: an historical cohort study in 414 patients 114
Interferon-induced anti-HBE seroconversion correlates with a Th1 cytokine shift following emergence of core promoter mutations in chronic hepatitis B 113
Comunicazione orale: Cinetica precoce dell’HCV-RNA in pazienti con epatite cronica: correlati clinico-virologici e valore predittivo la risposta al trattamento antivirale 113
Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. 113
Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C 112
Embolia maggiore nell’endocardite infettiva: associazione con l’età e la risposta di fase acuta 112
Le infezioni respiratorie da Branhamella catarrhalis in pazienti sottoposti a trapianto di cuore. 112
Core promoter mutations 3 years after anti-hepatitis B e seroconversion in patients with chronic hepatitis B or hepatitis B and C infection and cancer remission 111
Epidemiology, clinical spectrum and prognostic value of mixed cryoglobulinaemia in hepatitis C virus patients: a prospective study 111
Treatment of chronic hepatitis B: efficacy of current drugs and prospects for the future 110
Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review 109
Effective itraconazole treatment of pulmonary aspergillosis in heart transplant patients 109
Ruolo patogenetico dell’adiponectina nella steatosi associata ad epatite C 109
Anthropometric parameters and liver histology influence lipid metabolic changes in HCV chronic hepatitis on direct-acting antiviral treatment 109
Effects of long-term alfa interferon treatment in 344 patients with chronic hepatitis C: retrospective analysis of dosage and type of interferon used 108
Tm6sf2 e167k variant is associated with severe steatosis in chronic hepatitis c, regardless of pnapl3 polymorphism 108
Long term effect of interferon (IFN) treatment of chronic hepatitis B (CHB) in pediatric patients cured of oncologic diseases 108
The TM6SFZ 8167K variant is an independent predictor of severe liver steatosis in chronic hepatitis C 108
Polimorfismo di IL28B nei soggetti con infezione cronica da HCV con transaminasi persistentemente normali e nei pazienti con epatite cronica d HCV 107
Different serological, molecular and cytokine profiles characterize active and inactive disease in patients with chronic hepatitis B virus (HBV) infection 107
Occult HBV infection in the oncohematological setting. 107
Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. 107
Decrease in HDV endemicity in Italy 106
Disordini immunologici in corso di epatite cronica da HCV: prevalenza significato clinico ed implicazioni terapeutiche. 106
ESPERIENZA CON L'INTERFERONE LINFOBLASTOIDE NELLE EPATITI CRONICHE VIRALI 106
Treatment of chronic HBV infection in developing countries. 106
Mild chronic hepatitis C with steatosis: Which treatment? 105
Favourable effect of alpha-interferon treatment in HBeAb/HBV-DNA positive chronic hepatitis B 105
Le infezioni delle basse vie urinarie: eziologia e suscettibilità agli antibiotici. Nostra esperienza negli ultimi 4 anni. 105
Incidence, Risk Factors and Clinical Implications of Glucose Metabolic Changes after Heart Transplant 104
Hepatitis B virus DNA quantitation and detection of core promoter, precore and polymerase mutations in chronic hepatitis B: evaluation and clinical usefulness of three new commercial assays 104
Management of carbapenem resistant Enterobacteriaceae infections 104
Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection 103
The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients 103
Correlation of serum HBeAg levels and double A1762T/G1764A HBV core promoter mutation with response to interferon in patients with chronic hepatitis B 103
NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. 103
CANNABINOID RECEPTOR 2 (CB2) 63 QQ VARIANT IS ASSOCIATED WITH A SEVERE HISTOLOGICAL ACTIVITY INDEX IN PATIENTS WITH CHRONIC HEPATITIS C 103
Drugs and liver injury: a not to be overlooked binomial in COVID-19 103
Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis 102
Totale 12.176
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.552
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.552
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021939 0 0 0 0 0 7 227 183 13 233 202 74
2021/20221.445 58 13 4 14 482 19 26 44 63 149 109 464
2022/20232.898 261 48 31 222 333 222 10 165 1.467 25 56 58
2023/20241.177 93 28 41 72 420 181 34 35 6 13 88 166
2024/20253.722 8 48 32 84 589 594 560 311 443 578 322 153
2025/202611.934 461 570 677 744 1.137 8.345 0 0 0 0 0 0
Totale 25.683